IP Library Granted Patent US 10,227,635
Granted Patent B2
US 10,227,635 · App. 13/448,961 · Granted Mar 12, 2019

Capture reactions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,227,635
App. No.
13/448,961
Granted
Mar 12, 2019
Kind
B2
Abstract

The invention generally relates to methods of performing a capture reaction. In certain embodiments, the method involves obtaining a nucleic acid, fragmenting the nucleic acid, and capturing a target sequence on the nucleic acid fragment using a capture moiety, such as a molecular inversion probe.

Claims (23)

1. A method of performing a molecular inversion probe capture reaction, the method comprising:

denaturing a nucleic acid;

fragmenting the nucleic acid into nucleic acid fragments in order to expose a target site for a molecular inversion probe that was not exposed prior to fragmenting, wherein the fragmenting step occurs during the denaturing step, and wherein the nucleic acid is fragmented and denatured by heating the nucleic acid in a buffer system to shift a pH of the buffer system;

introducing a plurality of molecular inversion probes under conditions such that the molecular inversion probe hybridizes to the target site on the nucleic acid fragment, and wherein each of the plurality of molecular inversion probes is configured to capture a different subregion of the target site, and wherein each subregion is different and overlaps with at least one other subregion on the same strand;

circularizing the hybridized molecular inversion probe to form a circularized probe/target nucleic acid molecule;

isolating the circularized probe/target nucleic acid molecule;

linearizing the circularized probe/target nucleic acid molecule, thereby forming a linearized probe/target nucleic acid molecule;

conducting an amplification reaction with the linearized probe/target nucleic acid molecule to generate an amplification product, wherein the amplification reaction introduces a barcode sequence to the amplification product; and

sequencing the amplification product.

2. The method of claim 1 , further comprising the step of denaturing the nucleic acid or at least one nucleic acid fragment prior to the capturing step.

3. The method of claim 1 , wherein the nucleic acid fragments are from about 5 kb to about 100 kb in length.

4. The method of claim 1 , wherein the nucleic acid fragments are from about 1 kb to about 10 kb in length.

5. The method of claim 1 , wherein the nucleic acid is selected from the group of genomic DNA, genomic RNA, whole or partial genome amplification product, high molecular weight DNA, and high molecular weight RNA.

6. A method of improving performance of capture reactions using molecular inversion probes having two targeting arms, the method comprising:

denaturing a nucleic acid;

fragmenting the nucleic acid into nucleic acid fragments in order to expose a target site having one or more bases to molecular inversion probes that were not exposed prior to fragmenting, the molecular inversion probes being designed such that each molecular inversion probes is configured to capture a different subregion of the target site, and wherein each subregion is different and overlaps with at least one other subregion on the same strand, wherein the fragmenting step occurs during the denaturing step, and wherein the nucleic acid is fragmented and denatured by heating the nucleic acid in a buffer system to shift a pH of the buffer system;

introducing the molecular inversion probes under conditions such that the molecular inversion probes hybridize to the target site on the nucleic acid fragment;

circularizing the hybridized molecular inversion probes to form circularized probe/target nucleic acid molecules;

isolating the circularized probe/target nucleic acid molecules;

linearizing the circularized probe/target nucleic acid molecules, thereby forming linearized probe/target nucleic acid molecules;

conducting an amplification reaction with the linearized probe/target nucleic acid molecules to generate one or more amplification products, wherein the amplification reaction introduces a barcode sequence to the amplification products; and

sequencing the amplification products; and

wherein at least one targeting arm of each of the more than one molecular inversion probe does not hybridize to a same sequence of the nucleic acid.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2025
From: MOLECULAR LOOP BIOSCIENCES, INC.
To: MOLECULAR LOOP CORPORATION
Reel/Frame 070698/0955 →
CHANGE OF NAME Recorded Jul 12, 2023
From: MOLECULAR LOOP BIOSOLUTIONS, LLC
To: MOLECULAR LOOP BIOSCIENCES, INC.
Reel/Frame 064257/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2018
From: GOOD START GENETICS, INC.
To: MOLECULAR LOOP BIOSOLUTIONS, LLC
Reel/Frame 047459/0461 →
RELEASE OF SECURITY INTEREST Recorded Feb 23, 2018
From: WESTERN ALLIANCE BANK
To: GOOD START GENETICS, INC.
Reel/Frame 045020/0296 →
RELEASE OF SECURITY INTEREST Recorded Aug 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "B" L.P. FORMERLY CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: GOOD START GENETICS, INC.
Reel/Frame 043211/0658 →
SECURITY AGREEMENT Recorded Apr 30, 2013
From: GOOD START GENETICS, INC.
To: BRIDGE BANK, NATIONAL ASSOCIATION
Reel/Frame 030315/0963 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Apr 25, 2013
From: GOOD START GENETICS, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 030295/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2012
From: UMBARGER, MARK; PORRECA, GREGORY; TOWNE, CHARLES; CHURCH, GEORGE
To: GOOD START GENETICS, INC.
Reel/Frame 028403/0529 →
Cited By (1)
US 12,386,895